A Brief Review on Covid-19 Vaccines

Authors

  • A Narendranath Deparment of Pharmacovigilance Operations, Parexel International Private Limited, Hyderabad, Telangana, India.
  • VN Vamsi Krishna Deparment of Pharmacovigilance Operations, Parexel International Private Limited, Hyderabad, Telangana, India.
  • J Akhila Deparment of Pharmacovigilance Operations, Parexel International Private Limited, Hyderabad, Telangana, India.

DOI:

https://doi.org/10.61427/jcpr.v.i..48

Keywords:

Clinical trials, Covid-19, Vaccines

Abstract

Vaccines are biological products that can help body to acquire immunity against pathogen without occurrence of infection. During clinical trials, vaccines are tested in volunteers to ensure safety and effectiveness. As a part of phase 4 clinical stage, adverse effects are monitored regularly by the licensing authority. The benefit of vaccination is to reduce the risk of death and severe disease. Evidence suggests that it is very common to get side effects after covid-19 vaccination. These side effects usually disappear after few days of vaccination. The main aim of this review is to provide an overview of covid-19 vaccines in the present scenario.

Downloads

Download data is not yet available.

References

Biasio LR, Bonaccorsi G, Lorini C, Pecorelli S. Assessing COVID-19 vaccine literacy: a preliminary online survey. Hum Vaccines Immunother, 2020:1-9.

Vasileiou E, Simpson CR, Shi T et al. Interim findings from first dose mass Covid-19 vaccination roll-out and Covid-19 hospital admissions in Scotland: A national prospective cohort study. Lancet, 2021; 397: 1646-57.

Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine, 2013; 31:5634-42.

Ella R, Vadrevu KM, Jogdand H et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial. Lancet Infect Dis, 2021; 21:637-46.

Voysey M, Costa Clemens SA, Madhi SA et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet, 2021; 397: 881-91.

Ella R, Reddy S, Blackwelder W et al. Efficacy, safety and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet, 2021; 398(10317):2173-84.

Advisory Committee on Immunisation Practices. Booster dose of Janssen COVID-19 vaccine (Ad26.COV2.S) following primary vaccination. 2021.https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/03-COVID-Heaton-Douoguih-508. Pdf.

Andrews N, Tessier E, Stowe J et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv 2021; https://doi.org/10.1101/2021.09.15.21263583.

Pagotto V, Ferloni A, Soriano MM et al. Active surveillance of the Sputnik V vaccine in health workers. medRxiv 2021;https://doi.org/10.1101/2021.02.03.21251071.

Dey A, Chozhavel Rajanathan T, Chandra H, Pericherla H, Kumar S, Choonia H et al. Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARSCoV-2 in Animal Models. 2021; 5; 39(30):4108-16.

CTRI. Biological E’s Novel Covid-19 Vaccine of SARS-CoV-2 for Protection Against Covid-19 Disease: 2020.

Government of Delhi: Department of Information and Publicity. Delhi Fights Corona: COVID-19 response updates from the Delhi Government.2021: https://delhifightscorona.in.

Published

2022-01-31
Statistics
311 Views | 192 Downloads
Citatons

How to Cite

Narendranath, A., V. Vamsi Krishna, and J. Akhila. “A Brief Review on Covid-19 Vaccines”. Journal of Clinical and Pharmaceutical Research, Jan. 2022, pp. 1-3, doi:10.61427/jcpr.v.i. 48.

Issue

JCPR Volume:2/Issue:1 (2022)

Section

Review Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.